+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 0Years +
FEMALE
Healthy Volunteers
ID05908682

Safety Evaluation of Ibrexafungerp Exposure During Pregnancy Including Infant Health Outcomes up to One Year

Led by GlaxoSmithKline · Updated on 2026-09-23

100

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This observational study evaluates the safety of ibrexafungerp exposure during pregnancy. It focuses on pregnant women of any age who have taken ibrexafungerp while pregnant or conceived within four days after their last dose. The study aims to collect information on pregnancy outcomes, complications, and infant health up to one year after birth. Participants include pregnant women exposed to ibrexafungerp, who are monitored from the time of exposure through one year after a live delivery. Data are collected both retrospectively and prospectively through questionnaires completed by the participant or healthcare provider. This single-arm study does not involve any active intervention. During the study, researchers gather detailed information about pregnancy and infant outcomes, including the occurrence of major structural defects up to one year after birth. Participants may be contacted for interviews and asked to complete questionnaires. The study also collects data on pregnancy complications and infant health throughout the follow-up period. The total participation lasts from enrollment through one year after delivery.

CONDITIONS

Brief Title

Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes

Research Team

S

Sanjeev Miglani, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here